Lepper A W, Elleman T C, Hoyne P A, Lehrbach P R, Atwell J L, Schwartzkoff C L, Egerton J R, Tennent J M
CSIRO Division of Animal Health, Animal Health Research Laboratory, Parkville, Vic., Australia.
Vet Microbiol. 1993 Jul;36(1-2):175-83. doi: 10.1016/0378-1135(93)90138-w.
Pili (fimbriae) were prepared from Moraxella bovis strain Dalton 2d (Dal2d) and from a derivative of Pseudomonas aeruginosa K/2PfS that contained a plasmid-borne Dal2d pilin gene and produced pili having serogroup-specific identity to Dal2d. Nine calves were vaccinated with two doses each of 30 micrograms authentic M. bovis Dal2d pili in oil adjuvant and 10 calves were vaccinated with a similar dose of P. aeruginosa-derived Dal2d pili in the same formulation. All 19 calves and 10 non-vaccinated controls were challenged by instillation of 1 x 10(9) virulent M. bovis Dal2d cells into both conjunctival sacs 19 days after the second vaccine dose. The serological response to vaccination and the degree of protection against experimentally induced infectious bovine keratoconjunctivitis (IBK) were assessed. None of the nine calves vaccinated with authentic M. bovis Dal2d pili developed IBK while two of those vaccinated with P. aeruginosa-derived Dal2d pili developed lesions which accounted for a mean group lesion score of 0.3. In contrast, 9 of the 10 non-vaccinated calves developed IBK lesions, the majority of which were progressive, required early treatment and accounted for a mean group lesion score of 1.5. These results demonstrate the potential of a relatively low dose of pili produced by recombinant DNA technology for development of an effective vaccine against IBK.
从牛莫拉菌道尔顿2d菌株（Dal2d）以及铜绿假单胞菌K/2PfS的一个衍生物中制备菌毛（纤毛），该衍生物含有一个质粒携带的Dal2d菌毛蛋白基因，并产生与Dal2d具有血清群特异性相同的菌毛。9头小牛用两剂、每剂30微克的含油佐剂的牛莫拉菌Dal2d真实菌毛进行免疫接种，10头小牛用相同配方的类似剂量的源自铜绿假单胞菌的Dal2d菌毛进行免疫接种。在第二次疫苗接种后19天，向所有19头接种小牛和10头未接种对照小牛的双眼结膜囊中滴注1×10⁹个强毒牛莫拉菌Dal2d细胞进行攻毒。评估了对疫苗接种的血清学反应以及对实验性诱导的传染性牛角膜结膜炎（IBK）的保护程度。用牛莫拉菌Dal2d真实菌毛免疫接种的9头小牛中没有一头发生IBK，而用源自铜绿假单胞菌的Dal2d菌毛免疫接种的小牛中有两头出现病变，平均组病变评分为0.3。相比之下，10头未接种小牛中有9头出现IBK病变，其中大多数病变呈进行性发展，需要早期治疗，平均组病变评分为1.5。这些结果表明，通过重组DNA技术生产的相对低剂量菌毛具有开发有效抗IBK疫苗的潜力。
